The Re-Capitalisation announcement refers to Use of Funds. Phylogica will apply funds to specific activities as outlined in the announcement. That's not to say there aren't other programs ongoing and multiple other leads being advanced.
The biggie is of course Genentech. Thanks to Upxdn for his insight into the funding strategy. The other obvious lead is iMyc conjugates which is being progressed through a collaboration. Then there is work with Sir David Lane from A*Star. Further again are a couple of research programs which are pretty well compelling and could constitute breakthroughs of global significance. All of these are primarily funded from external sources including grants. Phylogica is focused upon its own internal programs - destiny in its own hands - but outside of that there are huge opportunities.
PYC Price at posting:
3.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)